ClinicalTrials.gg
Active, not recruitingNCT03833154PACIFIC-4Updated Nov 9, 2026

Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

A Phase 3 interventional study of Durvalumab and Placebo in Carcinoma, Non-Small-Cell Lung, sponsored by AstraZeneca. Active, not recruiting at 209 sites in 20 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
724
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 37 under way, 11 of them phase 3. durvalumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
7th of 94
724 · median 74
Started
2019
with 7 others
Phase 3
17 of 94
3 open now
Primary completion
2028-10
later than 30 of 36 live
Registered
39th of 94
by date
Lead sponsor
25 of 94
AstraZeneca

Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, this one is the 7th largest by enrollment, is one of 8 that started in 2019, is one of 17 in phase 3, reaches primary completion later than 30 of the 36 other live ones, and was the 39th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC.

An additional cohort will assess Osimertinib following SBRT in patients with early stage unresected T1 to T3N0M0 NSCLC harbouring an EGFR mutation.

Read the detailed description

Patients with Stage I/II lymph node negative NSCLC and confirmed to meet all eligibility criteria will be randomized 1:1 to receive either Durvalumab + SoC SBRT or placebo + SoC SBRT.

The primary objective of main cohort is to assess the efficacy of Durvalumab with SoC SBRT compared to placebo with SoC SBRT in terms of PFS. Key secondary is to assess the efficacy of Durvalumab with SoC SBRT compared to placebo with SoC SBRT in terms of Overall Survival (OS).

In addition, a study cohort with a sufficient number of patients harboring an EGFR-TKI sensitizing mutation, will receive Osimertinib treatment after completion of SoC SBRT as definitive treatment of Stage I/II lymph node-negative NSCLC. The primary objective of Osimertinib cohort is to assess efficacy of Osimertinib following SoC SBRT in terms of 4-year PFS. Key secondary objectives include safety, OS and efficacy of Osimertininb treatment with SBRT.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung

Keywords

  • NSCLC
  • Early-Stage NSCLC
  • Lung cancer
  • Double- Blind
  • PD-L1
  • MEDI4736
  • Durvalumab
  • Osimertinib
  • PFS
  • OS
  • Unresected lung cancer
  • Medically Inoperable
  • Operable with Patient refusal
  • SBRT
  • SABR
  • EGFR
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Cohort Key Inclusion Criteria:

  1. Age ≥18 years
  2. Planned SoC SBRT as definitive treatment
  3. World Health Organization (WHO)/ PS of 0, 1 or 2
  4. of at least 12 weeks
  5. Body weight >30 kg
  6. Submission of tumor tissue sample if available
  7. Adequate organ and marrow function required
  8. Patients with central or peripheral lesions are eligible
  9. Staging studies must be done during screening (PET-CT within 10 weeks)
  10. Patients with a history of metachronous NSCLC and synchronous lesions are eligible with some exceptions

Main Cohort Key Exclusion Criteria:

  1. Mixed small cell and non-small cell cancer
  2. History of allogeneic organ transplantation
  3. History of another primary with exceptions
  4. History of active primary immunodeficiency
  5. Epidermal growth factor receptor local testing is strongly recommended prior to enrollment. Patients with a tumor harboring an EGFRm per local testing will be excluded from the main cohort
  6. Prior exposure to immune-mediated therapy with exceptions

Osimertinib Cohort Key Inclusion Criteria

  1. Age ≥18 years
  2. Planned SoC SBRT as definitive treatment
  3. WHO/ECOG PS of 0, 1, or 2
  4. Patients with central or peripheral lesions are eligible
  5. Patients with a history of metachronous NSCLC and synchronous lesions are eligible with some exceptions
  6. Staging studies must be done during screening (PET-CT within 10 weeks)
  7. Submission of tumor tissue sample if available
  8. Confirmation by local laboratory that the tumor harbors one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R)
  9. Adequate bone marrow reserve or organ function required
  10. Female patients should be using highly effective measures
  11. Male patients should be asked to use barrier contraceptives (ie, condoms) during sex with all partners during the trial and avoid procreation

Osimertinib Cohort Key Exclusion Criteria

  1. Mixed small cell and non-small cell cancer
  2. Patients with known or increased risk factor for prolongation
  3. Treatment with any of the following:

    • Preoperative or platinum-based or other chemotherapy for the disease under investigation
    • Prior treatment with neoadjuvant or adjuvant EGFR TKI
    • Patients currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be potent inducers of
  4. nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of osimertinib
  5. Any of the following cardiac criteria

    • Mean resting corrected QT interval >470 msec, obtained from 3 ECGs
    • Any abnormalities in rhythm, conduction, or morphology of resting .
    • Any factors that increase the risk of QTc prolongation or risk of arrhythmic events, or unexplained -sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval
    • Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required treatment, or any evidence of clinically active ILD
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
724 participants (actual)

Study arms

  • Experimental
    SoC SBRT + Durvalumab Therapy (Main Cohort)

    SBRT Durvalumab (PD-L1 monoclonal antibody) 1500 mg every 4 weeks \[q4w\] intravenously \[iv\] for up to 26 cycles or until progression or other discontinuation criteria are met.

    Drug: Durvalumab

  • Placebo comparator
    SoC SBRT + Placebo Therapy (Main Cohort)

    SBRT Placebo (matching placebo for infusion) every 4 weeks iv for up to 26 cycles or until progression or other discontinuation criteria are met.

    Other: Placebo

  • Experimental
    SoC SBRT + Osimertinib Therapy (Osimertinib cohort, single-arm, open-label separate cohort)

    SBRT Osimertinib 80mg every day \[qd\] for oral administration up to 36 months or until progression. Osimertinib treatment should start within 7 to 14 days after completion of SBRT

    Drug: (Osimertinib cohort, single-arm, open-label separate cohort)

Interventions

  • Durvalumab 1500 mg every 4 weeks \[q4w\] intravenously \[iv\] for up to 26 cycles or until progression or other discontinuation criteria are met.

    Also known as: MEDI4736

  • OtherPlacebo

    Matching placebo for infusion every 4 weeks iv for up to 26 cycles or until progression or other discontinuation criteria are met.

  • Drug(Osimertinib cohort, single-arm, open-label separate cohort)

    Osimertinib 80 mg every day \[qd\] orally for up to 36 months or until progression or other discontinuation criteria are met. Osimertinib treatment should start from 7 to 14 days after completion of SBRT

This study also gives Osimertinib. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) assessed by Blinded Independent Central Review (BICR) according to RECIST 1.1 in subpopulation of patients with Stage I/II NSCLC

    Main Cohort

    Time frame: from randomization up to 6 years

  2. 4-year Progression-Free Survival (4y-PFS) by ICR according to RECIST 1.1 criteria

    Osimertinib Cohort

    Time frame: from treatment start up to 5 years

Secondary outcomes

  1. Progression-Free Survival (PFS) assessed by BICR per RECIST 1.1 in all randomised patients with Stage I/II NSCLC

    Main Cohort

    Time frame: from randomization up to 6 years

  2. Overall Survival (OS)

    Main Cohort

    Time frame: from randomization up to 7 years

  3. Concentration of durvalumab in serum such as peak concentration and trough

    Main Cohort

    Time frame: 12 weeks after last dose

  4. Detection of ADA neutralising antibodies titers

    Main Cohort

    Time frame: up to 6 months after last dose

  5. Health-related quality of life in patients treated with durvalumab with SoC SBRT compared to placebo with SoC SBRT using the EORTC QLQ-C30

    Main Cohort

    Time frame: from randomization up to 7 years

  6. Proportion of patients alive and progression free at 24 months from randomisation (PFS24) assessed by BICR according to RECIST 1.1

    Main Cohort

    Time frame: at 24 months following randomization

  7. Time to progression (TTP) assessed by BICR according to RECIST 1.1

    Main Cohort

    Time frame: from randomization up to 6 years

  8. Time to death or distant metastasis (TTDM) assessed by BICR according to RECIST 1.1

    Main Cohort

    Time frame: from randomization up to 6 years

  9. Time from randomisation to second progression (PFS2) as defined by local standard clinical practice

    Main Cohort

    Time frame: from randomization up to 7 years

  10. Assessment of AEs by CTCAE v 5.0 as measures of the safety and tolerability of Durvalumab with SoC SBRT compared to placebo with SoC SBRT

    Main Cohort

    Time frame: up to 3 months after last dose

  11. Assessment of AEs by CTCAE v 5.0 as measures of the safety, tolerability and compliance of osimertinib with SoC SBRT therapy

    Osimertinib Cohort

    Time frame: Up to 35 days after last dose

  12. WHO performance status

    Osimertinib Cohort

    Time frame: from treatment start up to 5 years

  13. ECG QT interval

    Osimertinib Cohort

    Time frame: Up to 156 weeks of treatment or treatment discontinuation

  14. Overall Survival

    Osimertinib Cohort

    Time frame: from treatment start up to 5 years

  15. Time To Progression (TTP)

    Osimertinib Cohort

    Time frame: from treatment start up to 5 years

  16. Time to CNS progression

    Osimertinib Cohort

    Time frame: from treatment start up to 5 years

  17. PFS2

    Osimertinib Cohort

    Time frame: from treatment start up to 5 years

  18. Site(s) of disease progression

    Osimertinib Cohort

    Time frame: from treatment start up to 5 years

  19. PFS by ICR using RECIST 1.1

    Osimertinib Cohort

    Time frame: from treatment start up to 5 years

Other outcomes

  1. Lung cancer mortality

    Osimertinib Cohort

    Time frame: from treatment start up to 5 years

  2. Lung Cancer Mortality

    Main Cohort

    Time frame: from randomization Up to 5 years

07

Study locations

209 sites
  • Research Site
    Tuscaloosa, Alabama 35401, United States
  • Research Site
    Chandler, Arizona 85224, United States
  • Research Site
    Phoenix, Arizona 85004, United States
  • Research Site
    Tucson, Arizona 85719, United States
  • Research Site
    Duarte, California 91010, United States
  • Research Site
    Long Beach, California 90806, United States
  • Research Site
    Los Angeles, California 90095, United States
  • Research Site
    San Diego, California 92123, United States
  • Research Site
    Newark, Delaware 10709, United States
  • Research Site
    Washington D.C., District of Columbia 20010, United States
  • Research Site
    Bay Pines, Florida 33744, United States
  • Research Site
    Jacksonville, Florida 32256, United States
  • Research Site
    Miami Beach, Florida 33140, United States
  • Research Site
    Orlando, Florida 32804, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Atlanta, Georgia 30342, United States
  • Research Site
    Chicago, Illinois 60611, United States
  • Research Site
    Chicago, Illinois 60612, United States
  • Research Site
    Chicago, Illinois 60637, United States
  • Research Site
    Decatur, Illinois 62526, United States
  • Research Site
    Elmhurst, Illinois 60126, United States
  • Research Site
    Naperville, Illinois 60540, United States
  • Research Site
    Fort Wayne, Indiana 46845, United States
  • Research Site
    Cedar Rapids, Iowa 52403, United States
  • Research Site
    Iowa City, Iowa 52242, United States
  • Research Site
    Elizabethtown, Kentucky 42701, United States
  • Research Site
    Lexington, Kentucky 40503, United States
  • Research Site
    Louisville, Kentucky 40202, United States
  • Research Site
    Metairie, Louisiana 70006, United States
  • Research Site
    New Orleans, Louisiana 70121, United States
  • Research Site
    South Portland, Maine 04106, United States
  • Research Site
    Annapolis, Maryland 21401, United States
  • Research Site
    Baltimore, Maryland 21201, United States
  • Research Site
    Rosedale, Maryland 21237, United States
  • Research Site
    Silver Spring, Maryland 20910, United States
  • Research Site
    Towson, Maryland 21204, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    Ann Arbor, Michigan 48197, United States
  • Research Site
    Detroit, Michigan 48201, United States
  • Research Site
    Royal Oak, Michigan 48073, United States
  • Research Site
    Duluth, Minnesota 55805, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    St Louis, Missouri 63110, United States
  • Research Site
    Omaha, Nebraska 68105, United States
  • Research Site
    Las Vegas, Nevada 89169, United States
  • Research Site
    Lebanon, New Hampshire 03756, United States
  • Research Site
    Camden, New Jersey 08103, United States
  • Research Site
    Paramus, New Jersey 07652, United States
  • Research Site
    Albany, New York 12206, United States
  • Research Site
    East Syracuse, New York 13057, United States
  • Research Site
    New Hyde Park, New York 11042, United States
  • Research Site
    New York, New York 10016, United States
  • Research Site
    Rochester, New York 14642, United States
  • Research Site
    Stony Brook, New York 11794, United States
  • Research Site
    Syracuse, New York 13210, United States
  • Research Site
    The Bronx, New York 10461, United States
  • Research Site
    The Bronx, New York 10467, United States
  • Research Site
    Winston-Salem, North Carolina 27157, United States
  • Research Site
    Grand Forks, North Dakota 58201, United States
  • Research Site
    Akron, Ohio 44304, United States
  • Research Site
    Blue Ash, Ohio 45242, United States
  • Research Site
    Cincinnati, Ohio 45219, United States
  • Research Site
    Cleveland, Ohio 44106, United States
  • Research Site
    Portland, Oregon 97210, United States
  • Research Site
    Portland, Oregon 97213, United States
  • Research Site
    Philadelphia, Pennsylvania 19107, United States
  • Research Site
    Pittsburgh, Pennsylvania 15212, United States
  • Research Site
    Charleston, South Carolina 29425, United States
  • Research Site
    Sioux Falls, South Dakota 57105, United States
  • Research Site
    Watertown, South Dakota 57201, United States
  • Research Site
    Austin, Texas 78745, United States
  • Research Site
    Dallas, Texas 75235, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Sherman, Texas 75090, United States
  • Research Site
    Burlington, Vermont 05401, United States
  • Research Site
    Richmond, Virginia 23249, United States
  • Research Site
    Bellingham, Washington 98225, United States
  • Research Site
    Seattle, Washington 98195, United States
  • Research Site
    Spokane Valley, Washington 99216, United States
  • Research Site
    Milwaukee, Wisconsin 53226, United States
  • Research Site
    Clayton, 3168, Australia
  • Research Site
    Aalst, 9300, Belgium
  • Research Site
    Charleroi, 6060, Belgium
  • Research Site
    Edegem, 2650, Belgium
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Porto Alegre, 90110-270, Brazil
  • Research Site
    Recife, 52010-075, Brazil
  • Research Site
    Rio de Janeiro, 22271-110, Brazil
  • Research Site
    São Paulo, 01327-001, Brazil
  • Research Site
    Volta Redonda, 27258-000, Brazil
  • Research Site
    Edmonton, Alberta T6G 1Z2, Canada
  • Research Site
    London, Ontario N6A 5W9, Canada
  • Research Site
    Toronto, Ontario M4N 3M5, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Montreal, Quebec H2X 3E4, Canada
  • Research Site
    Beijing, 100021, China
  • Research Site
    Beijing, 100142, China
  • Research Site
    Changchun, 130021, China

Showing the first 100 of 209 sites across 20 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2019 (actual). Primary completion is estimated for Oct 2028, 115 months after the start.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 115 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2019
First posted
Feb 6, 2019
StartActual
Mar 6, 2019
Primary completionEst.
Oct 31, 2028
CompletionEst.
Oct 31, 2028
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers, verification date and site details
1 update, last Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Minor edits only
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03833154
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 6, 2019
Start date
Mar 6, 2019
Primary completion
Oct 31, 2028 (estimated)
Completion
Oct 31, 2028 (estimated)
Last update
Nov 9, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Osimertinib

Start the discussion